Table: Sapporo Clinical Lab -2019/20 group results

Sapporo Clinical Laboratory

13/05/2020 07:30

May 13 (Reuters)- 
          Sapporo Clinical Laboratory Co Ltd 
          CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified)
                 Year ended      Year ended       Year to       NEXT   
              Mar 31, 2020    Mar 31, 2019   Mar 31, 2021     YEAR     
                 LATEST         YEAR-AGO        COMPANY      COMPANY   
                 RESULTS         RESULTS       FORECAST    H1 FORECAST 
  Sales           17.66           17.07          17.23         8.11    
               (+3.5 pct)      (-2.3 pct)     (-2.5 pct)    (-8.3 pct) 
  Operating      944 mln         815 mln        620 mln      165 mln   
               (+15.9 pct)     (-19.8 pct)    (-34.3 pct)  (-66.4 pct) 
  Recurring      982 mln         813 mln        635 mln      172 mln   
               (+20.9 pct)     (-22.8 pct)    (-35.4 pct)  (-66.1 pct) 
  Net
  Net            528 mln         523 mln        407 mln      105 mln   
               (+0.9 pct)      (-23.6 pct)    (-22.9 pct)  (-67.7 pct) 
  EPS          154.30 yen      152.42 yen     119.03 yen    30.79 yen  
  Ann Div       10.00 yen       10.00 yen      10.00 yen               
  -Q2 Div          NIL             NIL            NIL                  
  -Q4 Div       10.00 yen       10.00 yen      10.00 yen               
  
  NOTE - Sapporo Clinical Laboratory Co Ltd.
  *Second Net profit row denotes profit attributable to owners ofthe parent 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=9776.T